Resmed Inc
XMUN:RME
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Resmed Inc
XMUN:RME
|
US |
|
J
|
JB Hi-Fi Ltd
SWB:JB3
|
AU |
|
C
|
CapitaLand Integrated Commercial Trust
XBER:M3T
|
SG |
|
F
|
Fortescue Ltd
SWB:FVJ
|
AU |
|
D'Ieteren Group NV
OTC:SIEVF
|
BE |
|
Kering SA
OTC:PPRUF
|
FR |
|
R
|
Resmed Inc
XBER:RME
|
US |
|
Credit Agricole SA
PAR:ACA
|
FR |
|
Luk Fook Holdings (International) Ltd
F:LUY1
|
HK |
|
F
|
Five Below Inc
F:6F1
|
US |
|
U
|
United Natural Foods Inc
F:UN3
|
US |
|
W
|
Woolworths Group Ltd
SWB:WWR
|
AU |
|
Wilmar International Ltd
SGX:F34
|
SG |
Resmed Inc
Resmed makes devices and software for people with sleep apnea, COPD, and other breathing disorders. Its main products are CPAP and bilevel machines, masks, and other patient interface products that help people breathe more easily at home while they sleep. It also sells cloud-connected software that helps doctors, sleep clinics, and home medical equipment providers track treatment and manage patients. The company earns money in two main ways: by selling the hardware upfront and by selling replacement masks, supplies, and software-related services over time. Its customers are not usually patients buying directly at a store; they are more often healthcare providers, durable medical equipment suppliers, and insurers that support diagnosis, treatment, and long-term care. That gives Resmed a mix of one-time equipment sales and recurring follow-on sales. What makes Resmed’s business different is that it sits at the center of long-term sleep and respiratory therapy. The machines and masks need regular replacement, and the connected software helps keep patients on therapy and gives providers data they can use to manage care. That combination of devices, consumables, and digital monitoring makes Resmed both a medical device maker and a service provider in the home healthcare chain.
Resmed makes devices and software for people with sleep apnea, COPD, and other breathing disorders. Its main products are CPAP and bilevel machines, masks, and other patient interface products that help people breathe more easily at home while they sleep. It also sells cloud-connected software that helps doctors, sleep clinics, and home medical equipment providers track treatment and manage patients.
The company earns money in two main ways: by selling the hardware upfront and by selling replacement masks, supplies, and software-related services over time. Its customers are not usually patients buying directly at a store; they are more often healthcare providers, durable medical equipment suppliers, and insurers that support diagnosis, treatment, and long-term care. That gives Resmed a mix of one-time equipment sales and recurring follow-on sales.
What makes Resmed’s business different is that it sits at the center of long-term sleep and respiratory therapy. The machines and masks need regular replacement, and the connected software helps keep patients on therapy and gives providers data they can use to manage care. That combination of devices, consumables, and digital monitoring makes Resmed both a medical device maker and a service provider in the home healthcare chain.
Strong quarter: ResMed said Q3 revenue rose 11% to $1.43 billion, with operating margin expansion and $520 million of free cash flow.
Margins improved: Gross margin increased 290 basis points year over year to 62.8%, helped by component cost improvements and manufacturing/logistics efficiencies.
Big strategic move: ResMed announced a $340 million deal to buy Noctrix Health, expanding into restless leg syndrome and adding a faster-growing, higher-margin business.
Demand drivers: Management said fabric masks, AirSense 11 rollout, and increased screening and diagnosis of sleep apnea are supporting growth, while GLP-1 awareness is bringing more patients into the funnel.
Guidance held: The company kept fiscal 2026 margin guidance unchanged, including gross margin of 62% to 63%, SG&A of 19% to 20%, and R&D of 6% to 7%.
Capital return: ResMed returned $262 million to shareholders in the quarter and said it plans at least $175 million of buybacks in Q4, alongside a $0.60 quarterly dividend.
